4 - methyl - 3 - [[4 - (3-pyridinyl) - 2 - pirimidinil] - amino] - N - [5 - (4 - methyl - 1H imidazol-1-yl) - 3 - (trifluoro methyl) phenyl] - benzamide Amorphous, dosage form that contains it and Method for preparing them

• 收藏
• 分享

专利权人:

NOVARTIS AG

发明人:

申请号：

ARP120102086

公开号：

AR086913A1

申请日:

2012.06.12

申请国别(地区):

AR

年份:

2014

代理人:

摘要：

Claim 1: 4 - methyl - 3 - [[4 - (3-pyridinyl) - 2 - pirimidinil] - amino] - N - [5 - (4 - methyl - 1H imidazol-1-yl) - 3 - (trifluoro methyl) phenyl] - benzamide Amorphous, or Salt the pharmaceutically acceptable.Claim 2: a dosage form comprising 4 - methyl - 3 - [[4 - (3-pyridinyl) - 2 - pirimidinil] - amino] - N - [5 - (4 - methyl - 1H imidazol-1-yl) - 3 - (trifluoro methyl) phenyl] - benzamide Amorphous, or a pharmaceutically acceptable Salt of the same.Reivindicación 1: Una 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-N-[5-(4-metil-1H-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, o una sal farmacéuticamente aceptable de la misma.Reivindicación 2: Una forma de dosificación que comprende la 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-N-[5-(4-metil-1H-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, o una sal farmacéuticamente aceptable de la misma.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/